A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

NCT04967625 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Sintilimab
DRUG: Anlotinib hydrochloride

Sponsor

Zhejiang Cancer Hospital